# SS Innovations International, Inc.: overview SSII · Nasdaq · CIK 1676163 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ssii.md) · [Financials](/companies/ssii/financials.md) · [Filings](/companies/ssii/filings.md) · [Insiders](/companies/ssii/insiders.md) Latest reported revenue: [$13.9m](/filings/0001213900-26-088721.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001213900-26-088721). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [4.4](/filings/0001213900-25-103135.md) | [8.1 d](/filings/0001213900-26-025440.md) | [5.1](/filings/0001213900-26-055403.md) | [10.0](/filings/0001213900-25-072563.md) | [12.8](/filings/0001213900-25-103135.md) | [14.5 d](/filings/0001213900-26-025440.md) | [11.1](/filings/0001213900-26-055403.md) | [13.9](/filings/0001213900-26-088721.md) | | Gross margin | % | [52.8%](/filings/0001213900-25-103135.md) | [48.9% d](/filings/0001213900-26-025440.md) | [21.2%](/filings/0001213900-26-055403.md) | [59.1%](/filings/0001213900-26-088721.md) | [48.1%](/filings/0001213900-25-103135.md) | [43.9% d](/filings/0001213900-26-025440.md) | [48.0%](/filings/0001213900-26-055403.md) | [50.9%](/filings/0001213900-26-088721.md) | | Operating margin | % | [(73.1%)](/filings/0001213900-25-103135.md) | [(22.7%) d](/filings/0001213900-26-025440.md) | [(115.6%)](/filings/0001213900-26-055403.md) | [1.0%](/filings/0001213900-26-088721.md) | [(14.3%)](/filings/0001213900-25-103135.md) | [(5.1%) d](/filings/0001213900-26-025440.md) | [(32.8%)](/filings/0001213900-26-055403.md) | [(16.3%)](/filings/0001213900-26-088721.md) | | Net margin | % | [(74.0%)](/filings/0001213900-25-103135.md) | [(23.7%) d](/filings/0001213900-26-025440.md) | [(111.0%)](/filings/0001213900-26-055403.md) | [(2.6%)](/filings/0001213900-26-088721.md) | [(29.0%)](/filings/0001213900-25-103135.md) | [(17.0%) d](/filings/0001213900-26-025440.md) | [(32.3%)](/filings/0001213900-26-055403.md) | [(19.1%)](/filings/0001213900-26-088721.md) | | Diluted EPS | $ per share | [(0.02)](/filings/0001213900-25-103135.md) | not reported | [(0.03)](/filings/0001213900-26-055403.md) | [0.00](/filings/0001213900-26-088721.md) | [(0.02)](/filings/0001213900-25-103135.md) | not reported | [(0.02)](/filings/0001213900-26-055403.md) | [(0.01)](/filings/0001213900-26-088721.md) | | Free cash flow | $m | [(4.2) d](/filings/0001213900-25-103135.md) | [(3.4) d](/filings/0001213900-26-025440.md) | [(7.0)](/filings/0001213900-26-055403.md) | [(3.8) d](/filings/0001213900-26-088721.md) | [(8.2) d](/filings/0001213900-25-103135.md) | [(3.2) d](/filings/0001213900-26-025440.md) | [(2.4)](/filings/0001213900-26-055403.md) | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [1.4](/filings/0001213900-24-110779.md) | [5.9](/filings/0001213900-24-110779.md) | [20.6](/filings/0001213900-26-025440.md) | [42.5](/filings/0001213900-26-025440.md) | | Gross margin | % | not reported | [4.2%](/filings/0001213900-24-110779.md) | [12.3%](/filings/0001213900-25-031773.md) | [40.9%](/filings/0001213900-26-025440.md) | [46.0%](/filings/0001213900-26-025440.md) | | Operating margin | % | not reported | [(206.0%)](/filings/0001213900-24-110779.md) | [(345.1%)](/filings/0001213900-25-031773.md) | [(91.9%)](/filings/0001213900-26-025440.md) | [(19.3%)](/filings/0001213900-26-025440.md) | | Net margin | % | not reported | [(223.8%)](/filings/0001213900-24-110779.md) | [(355.4%)](/filings/0001213900-25-031773.md) | [(92.7%)](/filings/0001213900-26-025440.md) | [(28.5%)](/filings/0001213900-26-025440.md) | | Diluted EPS | $ per share | [(0.05)](/filings/0001213900-23-025143.md) | [(0.03)](/filings/0001213900-24-110779.md) | [(0.14)](/filings/0001213900-25-031773.md) | [(0.11)](/filings/0001213900-26-025440.md) | [(0.06)](/filings/0001213900-26-025440.md) | | Free cash flow | $m | not reported | [(6.2)](/filings/0001213900-24-110779.md) | [(15.8)](/filings/0001213900-25-031773.md) | [(10.2)](/filings/0001213900-26-025440.md) | [(22.2)](/filings/0001213900-26-025440.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ssii/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Hood River Capital Management LLC](/funds/1578177.md) | 2026-06-30 | $3.5m | 833,333 | | Unchanged | | [Inspire Investing, LLC](/funds/1670139.md) | 2026-06-30 | $773.1k | 186,297 | | Added +81,673 | | [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $457.2k | 110,157 | | Unchanged | | [JNBA Financial Advisors](/funds/1569118.md) | 2026-06-30 | $424.5k | 102,291 | | Reduced −14,646 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $212.5k | 51,208 | | Reduced −104,333 | | [AlphaCentric Advisors LLC](/funds/1913464.md) | 2026-06-30 | $207.5k | 50,000 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $173.3k | 41,771 | | Added +5,495 | | [Forum Financial Management, LP](/funds/1911832.md) | 2026-06-30 | $159.6k | 38,469 | | Unchanged | | [AlTi Global, Inc.](/funds/1838615.md) | 2026-06-30 | $85.3k | 20,555 | | Unchanged | | [Mariner, LLC](/funds/1373442.md) | 2026-06-30 | $79.7k | 19,211 | | Added +554 | ## Recent filings [All 309 filings](/companies/ssii/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 08:30 ET | [8-K](/filings/0001213900-26-112292.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-112292 | | 2026-10-13 | 09:26 ET | [8-K](/filings/0001213900-26-108792.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-108792 | | 2026-10-13 | 06:05 ET | [8-K](/filings/0001213900-26-108624.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001213900-26-108624 | | 2026-10-05 | 08:00 ET | [8-K](/filings/0001213900-26-106654.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-106654 | | 2026-09-10 | 08:30 ET | [8-K](/filings/0001213900-26-098588.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-098588 | | 2026-08-26 | 16:05 ET | [8-K](/filings/0001213900-26-093946.md) | 5.02 Departure or appointment of officers or directors | 0001213900-26-093946 | | 2026-08-13 | 08:30 ET | [8-K](/filings/0001213900-26-088726.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-26-088726 | | 2026-08-13 | 08:15 ET | [10-Q](/filings/0001213900-26-088721.md) | Quarterly report, period 2026-06-30 | 0001213900-26-088721 | | 2026-07-17 | 09:29 ET | [8-K](/filings/0001213900-26-078945.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-078945 | | 2026-07-14 | 08:35 ET | [8-K](/filings/0001213900-26-077784.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-077784 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-025440.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/2125f8bf-1380-4ac0-8711-5ebb4bbe672a) ## About the filer - CIK: 1676163 - Tickers: SSII - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: FL - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 08:31 ET. No prices; not investment advice.